{ "ok": true, "cik": "880242", "ticker": "BLGO", "name": "BIOLARGO, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-11", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/880242/000143774926030124/0001437749-26-030124-index.htm" }, { "form": "10-Q", "filed": "2026-08-14", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/880242/000143774926028023/0001437749-26-028023-index.htm" }, { "form": "10-Q", "filed": "2026-05-15", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/880242/000143774926017391/0001437749-26-017391-index.htm" }, { "form": "8-K", "filed": "2026-05-06", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/880242/000143774926014996/0001437749-26-014996-index.htm" }, { "form": "8-K", "filed": "2026-05-04", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/880242/000143774926014540/0001437749-26-014540-index.htm" }, { "form": "S-1", "filed": "2026-04-09", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/880242/000143774926011880/0001437749-26-011880-index.htm" } ], "events12m": 9, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000880242.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=880242" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up BIOLARGO, INC. ($BLGO). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-09-11. 9 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 7765000, "revenueGrowth1y": -0.5632487766466056, "revenueGrowthPerYear": 0.3234645982704456, "yearsOfData": 5, "operatingMargin": -1.9130714745653574, "operatingMarginPrior": -0.2436020023623376, "netMargin": -1.956084996780425, "operatingCashFlow": -8297000, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": 2593000, "researchShareOfRevenue": 0.3339343206696716, "cash": 3883000, "longTermDebt": 2079000, "longTermDebtChange": 0.9267840593141798, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 2531000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 5884000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 12230000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 17779000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 7765000 } ], "totalEquity": 4042000, "totalAssets": 8311000, "equityRatio": 0.4863434003128384, "returnOnEquity": -3.7577931716971795, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 4369857.286585755, "high": 7846570.285137904, "baseline": 5954295.253557371, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 4369857.286585755, "high": 7846570.285137904 } }, "edgarette": "🔖 Exposure: revenue $7.8M (FY2025), total debt $2.1M. Experience: revenue down 56.3% on the year, up 32.3% a year over 4 years; operating margin -191.3%, down from -24.4%. Soundness: equity 48.6% of assets, return on equity -375.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.4M and $7.8M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (9 filers, $50M+ revenue, chemicals & allied products): operating margin -191.3% against a 0.1% median; growth -56.3% against 0.4%.", "peers": { "sic": 2800, "sicDescription": "Chemicals & Allied Products", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2800", "growth": [ 0.0045, 11 ], "opMargin": [ 0.0008, 9 ], "equityRatio": [ 0.392, 11 ], "returnOnEquity": [ -0.1105, 10 ] }, "summary": "Biolargo (BLGO) saw revenue fall 56.3% in FY2025 to $8 million, operating margin -191% against a 0.1% median for chemicals & allied products, equity 48.6% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
BIOLARGO, INC. against its own record and its peers
Operating marginPeer median 0.1%-191.3%Revenue, on the yearPeer median 0.4%-56.3%Equity of assetsPeer median 39.2%48.6%Return on equityPeer median -11.1%-375.8%Gold tick: the median of 10–11 peers with $50M+ revenue in chemicals & allied products
", "chartHorizon": null, "backtest": { "tests": 12, "hits": 4, "rate": 0.3333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:23:09.134Z", "hash": "c90a220ee29afdaa", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Biolargo (BLGO) saw revenue fall 56.3% in FY2025 to $8 million, operating margin -191% against a 0.1% median for chemicals & allied products, equity 48.6% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 7765000, "totalDebt": 2079000, "cash": 3883000 }, "experience": { "revenueGrowth1y": -0.5632487766466056, "revenueGrowthPerYear": 0.3234645982704456, "operatingMargin": -1.9130714745653574, "operatingMarginPrior": -0.2436020023623376, "netMargin": -1.956084996780425, "freeCashFlow": null }, "soundness": { "equityRatio": 0.4863434003128384, "returnOnEquity": -3.7577931716971795, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2800, "sicDescription": "Chemicals & Allied Products", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2800", "growth": [ 0.0045, 11 ], "opMargin": [ 0.0008, 9 ], "equityRatio": [ 0.392, 11 ], "returnOnEquity": [ -0.1105, 10 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 4369857.286585755, "high": 7846570.285137904, "baseline": 5954295.253557371, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 12, "hits": 4, "rate": 0.3333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:23:09.134Z", "hash": "c90a220ee29afdaa", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000880242.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=880242" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }